ENLIVEN THERAPEUTICS, INC. Operating Lease, Expense
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Operating Lease, Expense of $81.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2024-11-13
- ENLIVEN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2024-09-30 was $81.00K, a 0.00% change year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2024-06-30 was $81.00K, a 1.22% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2023-09-30 was $81.00K, a 19.00% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating lease, expense for the quarter ending 2023-06-30 was $82.00K, a 59.00% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating lease, expense for fiscal 2022 was $500.00K, a 66.67% increase from fiscal 2021.
- ENLIVEN THERAPEUTICS, INC. operating lease, expense for fiscal 2021 was $300.00K, a 50.00% increase from fiscal 2020.
- ENLIVEN THERAPEUTICS, INC. operating lease, expense for fiscal 2020 was $200.00K, a 0.00% change from fiscal 2019.
- ENLIVEN THERAPEUTICS, INC. operating lease, expense for fiscal 2019 was $200.00K.
| Period end | Operating Lease, Expense 1 month | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|
| 2024-09-30 | $81.00K 10-Q · filed 2024-11-13 | $162.00K derived: sum of 2 quarters · filed 2024-11-13 | $244.00K 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | $81.00K 10-Q · filed 2024-08-13 | $163.00K 10-Q · filed 2024-08-13 | |||
| 2023-09-30 | $81.00K 10-Q · filed 2024-11-13 | $163.00K derived: sum of 2 quarters · filed 2024-11-13 | $244.00K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $82.00K 10-Q · filed 2024-08-13 | $163.00K 10-Q · filed 2024-08-13 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $100.00K derived: sum of 2 quarters · filed 2023-02-10 | $300.00K derived: sum of 3 quarters · filed 2023-02-10 | $500.00K 10-K · filed 2023-02-10 | |
| 2022-09-30 | $100.00K 10-Q · filed 2022-10-25 | $300.00K derived: sum of 2 quarters · filed 2022-10-25 | $500.00K 10-Q · filed 2022-10-25 | ||
| 2022-06-30 | $200.00K 10-Q · filed 2022-08-03 | $300.00K 10-Q · filed 2022-08-03 | |||
| 2022-03-31 | $100.00K 10-Q · filed 2022-05-06 | ||||
| 2021-12-31 | $300.00K 10-K · filed 2023-02-10 | ||||
| 2021-03-31 | $12.00K 10-Q · filed 2024-11-13 | $100.00K 10-Q · filed 2022-05-06 | $100.00K derived: sum of 2 quarters · filed 2022-05-06 | $200.00K derived: sum of 3 quarters · filed 2022-05-06 | $200.00K derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $100.00K derived: sum of 2 quarters · filed 2021-03-05 | $100.00K derived: sum of 3 quarters · filed 2021-03-05 | $200.00K 10-K · filed 2021-03-05 | |
| 2020-09-30 | $100.00K 10-Q · filed 2020-11-05 | $100.00K derived: sum of 2 quarters · filed 2020-11-05 | $200.00K 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $100.00K 10-Q · filed 2020-08-14 | |||
| 2020-03-31 | $100.00K 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $200.00K 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |